Pompeyo Viciana1, Antonio Ocampo2, Henar Hevia3, Marta Palazuelos3, Francisco Ledesma3. 1. Servicio Enf. Infecciosas, Hospital Universitario Virgen del Rocío, Sevilla, España. Electronic address: pompeyov@gmail.com. 2. Unidad VIH. Med. Interna, Hospital Xeral Cíes, Vigo, España. 3. Medical Affairs Manager, Janssen, Madrid, España.
Abstract
INTRODUCTION: The purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice. METHODS: An observational retrospective study performed in 65 Spanish hospitals. RESULTS: Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count<350 cells/μl. CONCLUSION: The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role.
INTRODUCTION: The purpose of Perfil-es study was to identify the proportion of patients starting ARV treatment based on NNRTIs or PI/r, and to identify the variables involved in the therapeutic decision-making in standard clinical practice. METHODS: An observational retrospective study performed in 65 Spanish hospitals. RESULTS: Was a total of 1,687 starts: 53% with NNRTI-based regimen and 42% with PI/r, and of the 642 patients analyzed, 72% had a CD4 count<350 cells/μl. CONCLUSION: The initiation of ARV treatment is still late in Spain. NNRTIs are the more frequent choice, although PI/r plays an important role.
Keywords:
Antiretroviral treatment; Human immunodeficiency virus; Inhibidor de la proteasa potenciado con ritonavir; Inhibidor de la transcriptasa inversa no análogo de nucleósidos; Naive; Non-nucleoside reverse transcriptase inhibitors; Protease inhibitors; Tratamiento antirretroviral; Virus de la inmunodeficiencia humana
Authors: Marta Ruiz-Algueró; Victoria Hernando; María Riero; José Ramón Blanco Ramos; Miguel Alberto de Zarraga Fernández; Pepa Galindo; Alexandre Pérez-González; Asunción Díaz; Inés Suárez-García; Inma Jarrín Journal: J Clin Med Date: 2022-03-29 Impact factor: 4.241